News - Excalibur - Randomized Controlled Trial

NewsJohn Brataas2022-05-24T20:05:55+00:00

News

505, 2023

May 2023: SLV/REK approved the extension of the Excalibur 2 trial ensuring continued inclusion also following the first analysis at 45 patients

By John Brataas|2023-09-05T08:20:41+00:00May 5, 2023|Categories: Uncategorized|0 Comments

504, 2023

April 2023: SLV/REK approved the 2c-stratum

By John Brataas|2023-09-05T08:19:57+00:00April 5, 2023|Categories: Uncategorized|0 Comments

108, 2022

New supplier of floxuridine

By John Brataas|2022-08-01T10:05:45+00:00August 1, 2022|Categories: Uncategorized|0 Comments

From July -22 Cerona Therapeutics will supply floxuridine through Cardinal [...]

2206, 2022

Updated information for ward and local hospitals has been posted on the archive

By John Brataas|2022-06-22T20:42:58+00:00June 22, 2022|Categories: Uncategorized|0 Comments

Download [...]

606, 2022

MRI compatibility

By John Brataas|2022-06-07T09:53:23+00:00June 6, 2022|Categories: Uncategorized|0 Comments

Tricumed have applied for renewed MRI-compatibility for the pump [...]

1505, 2022

Status of exCalibur 1, 2 and 3
Gallery
Status of exCalibur 1, 2 and 3

Uncategorized

Status of exCalibur 1, 2 and 3

By John Brataas|2022-05-24T20:12:03+00:00May 15, 2022|Categories: Uncategorized|0 Comments

EXCALIBUR 1 and EXCALIBUR2 are steadily recruiting patients aiming [...]